These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 831872)

  • 1. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis.
    Chiu HM; Hirsh J; Yung WL; Regoeczi E; Gent M
    Blood; 1977 Feb; 49(2):171-84. PubMed ID: 831872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indium-111-labeled platelets: effects of heparin on uptake by venous thrombi and relationship to the activated partial thromboplastin time.
    Fedullo PF; Moser KM; Moser KS; Konopka R; Hartman MT
    Circulation; 1982 Sep; 66(3):632-7. PubMed ID: 7094273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo.
    Boneu B; Buchanan MR; Cade JF; Van Ryn J; Fernandez FF; Ofosu FA; Hirsh J
    Thromb Res; 1985 Oct; 40(1):81-9. PubMed ID: 4089829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
    Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
    Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
    Fioravanti C; Burkholder D; Francis B; Siegl PK; Gibson RE
    Thromb Res; 1993 Aug; 71(4):317-24. PubMed ID: 8236160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis.
    Silver PJ; Broughton R; Bouthillier J; Quinn TA; Wallace AM; Weishaar RE
    Thromb Res; 1998 Aug; 91(3):143-50. PubMed ID: 9733158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits.
    Agnelli G; Pascucci C; Cosmi B; Nenci GG
    Thromb Haemost; 1991 Nov; 66(5):592-7. PubMed ID: 1839474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A study of human annexin V derivative: its effects of anticoagulation and antithrombosis].
    Ju CW; Wang LS; Yang X; Ma GS; Hua ZC; Gao XY
    Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):540-3. PubMed ID: 15569533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the quantitative action of protamine and heparin on blood coagulation. Significance in clinical and laboratory usage.
    Perkash A
    Am J Clin Pathol; 1980 May; 73(5):676-81. PubMed ID: 7377134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
    Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
    Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
    Kaiser B; Hauptmann J; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy in deep vein thrombosis and pulmonary embolism.
    Hirsh J
    Am Heart J; 1992 Apr; 123(4 Pt 2):1115-22. PubMed ID: 1553881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
    Agnelli G; Pascucci C; Cosmi B; Nenci GG
    Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intersubject variability in the anticoagulant response to heparin in vitro.
    Bjornsson TD; Wolfram KM
    Eur J Clin Pharmacol; 1982; 21(6):491-7. PubMed ID: 6176454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.